Baidu
map

Cell:宿主特异性微生物丛诱导免疫系统成熟

2012-07-03 bo 生物谷

6月21日,Cell杂志报道了宿主特异性微生物丛在诱导免疫系统成熟过程中作用的重要研究进展。 肠道微生物诱导宿主的免疫系统成熟,充分体现了宿主 - 微生物共生关系。研究者移植小鼠微生物丛(MMB)或人类微生物丛(HMB)到无微生物(GF)小鼠小肠中,以确定是否小肠免疫成熟取决于宿主特异性的微生物共同进化。 研究显示,肠道细菌的数量和细菌分类门 (phylum)的丰度在MMB和HMB小鼠小肠中是


6月21日,Cell杂志报道了宿主特异性微生物丛在诱导免疫系统成熟过程中作用的重要研究进展。

肠道微生物诱导宿主的免疫系统成熟,充分体现了宿主 - 微生物共生关系。研究者移植小鼠微生物丛(MMB)或人类微生物丛(HMB)到无微生物(GF)小鼠小肠中,以确定是否小肠免疫成熟取决于宿主特异性的微生物共同进化。

研究显示,肠道细菌的数量和细菌分类门 (phylum)的丰度在MMB和HMB小鼠小肠中是类似的,但细菌种类不同,尤其是厚壁菌门细菌的含量不同。 HMB小鼠肠道有低水平的CD4 +和CD8 + T细胞;增殖T细胞和树突状细胞也很少;同时,抗菌肽的表达也比较低。这些都是类似于GF小鼠的特点。

大鼠的微生物丛也未能充分扩大小鼠肠道T细胞的数量。给GF或HMB小鼠移植小鼠分段丝状菌(SFB)可部分恢复T细胞数量。这表明SFB和其他MMB微生物是诱导小鼠免疫功能充分成熟所必需的。重要的是,MMB比HMB能更好地保护小鼠免受沙门氏菌感染。可见,宿主特异性微生物丛,对于一个健康的免疫系统是何等地关键!

这项研究,也为防止滥用抗生素,维护正常肠道菌群带来很大的启发。

doi:10.1016/j.cell.2011.10.017
PMC:

PMID:

Gut Immune Maturation Depends on Colonization with a Host-Specific Microbiota

Hachung Chung, Sünje J. Pamp, Jonathan A. Hill, Neeraj K. Surana,et al

Gut microbial induction of host immune maturation exemplifies host-microbe mutualism. We colonized germ-free (GF) mice with mouse microbiota (MMb) or human microbiota (HMb) to determine whether small intestinal immune maturation depends on a coevolved host-specific microbiota. Gut bacterial numbers and phylum abundance were similar in MMb and HMb mice, but bacterial species differed, especially the Firmicutes. HMb mouse intestines had low levels of CD4+ and CD8+ T cells, few proliferating T cells, few dendritic cells, and low antimicrobial peptide expression—all characteristics of GF mice. Rat microbiota also failed to fully expand intestinal T cell numbers in mice. Colonizing GF or HMb mice with mouse-segmented filamentous bacteria (SFB) partially restored T cell numbers, suggesting that SFB and other MMb organisms are required for full immune maturation in mice. Importantly, MMb conferred better protection against Salmonella infection than HMb. A host-specific microbiota appears to be critical for a healthy immune system.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1868546, encodeId=ba39186854674, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Apr 17 06:08:00 CST 2013, time=2013-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1824546, encodeId=ac441824546ec, content=<a href='/topic/show?id=702a5065860' target=_blank style='color:#2F92EE;'>#微生物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50658, encryptionId=702a5065860, topicName=微生物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b7c20, createdName=wjcjjian, createdTime=Thu May 02 17:08:00 CST 2013, time=2013-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958778, encodeId=edf51958e7832, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Aug 14 02:08:00 CST 2012, time=2012-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899033, encodeId=0bbf1899033ee, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Wed Aug 08 22:08:00 CST 2012, time=2012-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404617, encodeId=3745140461e89, content=<a href='/topic/show?id=1a4f4649925' target=_blank style='color:#2F92EE;'>#宿主#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46499, encryptionId=1a4f4649925, topicName=宿主)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/08904ED76550A0090DB220A7FB81D755/100, createdBy=78512492586, createdName=wincls, createdTime=Thu Jul 05 07:08:00 CST 2012, time=2012-07-05, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1868546, encodeId=ba39186854674, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Apr 17 06:08:00 CST 2013, time=2013-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1824546, encodeId=ac441824546ec, content=<a href='/topic/show?id=702a5065860' target=_blank style='color:#2F92EE;'>#微生物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50658, encryptionId=702a5065860, topicName=微生物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b7c20, createdName=wjcjjian, createdTime=Thu May 02 17:08:00 CST 2013, time=2013-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958778, encodeId=edf51958e7832, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Aug 14 02:08:00 CST 2012, time=2012-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899033, encodeId=0bbf1899033ee, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Wed Aug 08 22:08:00 CST 2012, time=2012-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404617, encodeId=3745140461e89, content=<a href='/topic/show?id=1a4f4649925' target=_blank style='color:#2F92EE;'>#宿主#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46499, encryptionId=1a4f4649925, topicName=宿主)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/08904ED76550A0090DB220A7FB81D755/100, createdBy=78512492586, createdName=wincls, createdTime=Thu Jul 05 07:08:00 CST 2012, time=2012-07-05, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1868546, encodeId=ba39186854674, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Apr 17 06:08:00 CST 2013, time=2013-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1824546, encodeId=ac441824546ec, content=<a href='/topic/show?id=702a5065860' target=_blank style='color:#2F92EE;'>#微生物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50658, encryptionId=702a5065860, topicName=微生物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b7c20, createdName=wjcjjian, createdTime=Thu May 02 17:08:00 CST 2013, time=2013-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958778, encodeId=edf51958e7832, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Aug 14 02:08:00 CST 2012, time=2012-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899033, encodeId=0bbf1899033ee, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Wed Aug 08 22:08:00 CST 2012, time=2012-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404617, encodeId=3745140461e89, content=<a href='/topic/show?id=1a4f4649925' target=_blank style='color:#2F92EE;'>#宿主#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46499, encryptionId=1a4f4649925, topicName=宿主)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/08904ED76550A0090DB220A7FB81D755/100, createdBy=78512492586, createdName=wincls, createdTime=Thu Jul 05 07:08:00 CST 2012, time=2012-07-05, status=1, ipAttribution=)]
    2012-08-14 维他命
  4. [GetPortalCommentsPageByObjectIdResponse(id=1868546, encodeId=ba39186854674, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Apr 17 06:08:00 CST 2013, time=2013-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1824546, encodeId=ac441824546ec, content=<a href='/topic/show?id=702a5065860' target=_blank style='color:#2F92EE;'>#微生物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50658, encryptionId=702a5065860, topicName=微生物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b7c20, createdName=wjcjjian, createdTime=Thu May 02 17:08:00 CST 2013, time=2013-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958778, encodeId=edf51958e7832, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Aug 14 02:08:00 CST 2012, time=2012-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899033, encodeId=0bbf1899033ee, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Wed Aug 08 22:08:00 CST 2012, time=2012-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404617, encodeId=3745140461e89, content=<a href='/topic/show?id=1a4f4649925' target=_blank style='color:#2F92EE;'>#宿主#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46499, encryptionId=1a4f4649925, topicName=宿主)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/08904ED76550A0090DB220A7FB81D755/100, createdBy=78512492586, createdName=wincls, createdTime=Thu Jul 05 07:08:00 CST 2012, time=2012-07-05, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1868546, encodeId=ba39186854674, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Apr 17 06:08:00 CST 2013, time=2013-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1824546, encodeId=ac441824546ec, content=<a href='/topic/show?id=702a5065860' target=_blank style='color:#2F92EE;'>#微生物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50658, encryptionId=702a5065860, topicName=微生物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b7c20, createdName=wjcjjian, createdTime=Thu May 02 17:08:00 CST 2013, time=2013-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958778, encodeId=edf51958e7832, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Aug 14 02:08:00 CST 2012, time=2012-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899033, encodeId=0bbf1899033ee, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Wed Aug 08 22:08:00 CST 2012, time=2012-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404617, encodeId=3745140461e89, content=<a href='/topic/show?id=1a4f4649925' target=_blank style='color:#2F92EE;'>#宿主#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46499, encryptionId=1a4f4649925, topicName=宿主)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/08904ED76550A0090DB220A7FB81D755/100, createdBy=78512492586, createdName=wincls, createdTime=Thu Jul 05 07:08:00 CST 2012, time=2012-07-05, status=1, ipAttribution=)]
    2012-07-05 wincls

相关资讯

Cell Signal:下调整合素相关激酶表达抑制膀胱癌细胞转移

整合素相关激酶(ILK)是一种多功能的存在于细胞质中的丝氨酸/苏氨酸激酶。最近研究表明,ILK表达增高的癌症患者存活率低,预后差、转移率也升高。 虽然ILK过度表达的原因仍然有待阐明,但越来越多的研究发现了整合素相关激酶主要通过调控几个下游靶蛋白来实现其致癌能力,这些下游蛋白在肿瘤细胞的增殖、存活和迁移过程中发挥作用。 即使有了前期研究成果,ILK的促肿瘤转移的机制仍然没有完全得到解释。上皮间

Exp Cell Res:多靶抑制肿瘤诱导的血管生成

实体瘤的生长和转移需要血管生成,以确保迅速分裂的肿瘤细胞能获得充足的氧气、营养物质和生长因子。 血管内皮生长因子(VEGF)的转录因子是由HIF刺激调控的一个典型例子。化疗或放疗能引起肿瘤组织的缺氧反应,而血管内皮生长因子通过诱导血管生成促进肿瘤的生长和生存,可见VEGF对肿瘤的生长时至关重要的,因此VEGF已成为一个诱人靶标来治疗中晚期肿瘤患者,具体表现在运用一些VEGF的抗体来治疗患者。

J Mol Cell Biol:徐鹰等发现低氧可以驱动癌症生长

Journal of Molecular Cell Biology(《分子细胞生物学报》)2012年第3期“复杂疾病的系统生物学研究”专辑中发表了一篇美国佐治亚大学生物化学与分子生物学系徐鹰教授关于“Hypoxia and miscoupling between reduced energy efficiency and signaling to cell proliferation drive

Cancer Cell:胰腺癌治疗的新靶点

近日,一项新的研究发现胰腺癌细胞运用一种策略削弱免疫系统,使他肿瘤细胞自身能够逃脱免疫细胞的破坏。 这项研究由国家卫生研究院以及欧文顿研究所癌症研究所博士后奖学金计划等资助,并发表在Cancer Cell杂志上。 胰腺癌以其侵略性恶名昭彰。在过去五年中,只有4%的患者生存下来,目前可用的治疗胰腺癌的手段基本是无效的。 Dafna Bar-Sagi博士说:这是非常重要的,我们应了解如何中断这种

Mol Cell Bio:紧密连接蛋白促进乳腺癌肝转移

紧密连接蛋白与恶性肿瘤的发生和发展有着密切关系,Claudin蛋白是细胞间的紧密连接蛋白的主要结构之一。Claudin蛋白目前研究较多,其中与恶性肿瘤相关的Claudin蛋白主要有7种,不同的肿瘤组织表达的Claudin类蛋白种类、量是不同的,在研究恶性肿瘤诊断、治疗的新手段方面,Claudin蛋白有很大前景。 早期研究确定蛋白紧密连接-2(claudin-2)是乳腺癌肝转移的重要功能性调解因子

Cell Death & Differ:时玉舫等间充质干细胞介导的免疫调节获进展

间充质干细胞(MSCs)是在机体内广泛存在的一种具有多向分化潜能的组织干细胞。更由于其具有重要的免疫调节作用而受到重视,近些年来在疾病模式动物模型和临床研究上MSCs被尝试应用于治疗免疫紊乱疾病。尽管有不少文章报道称MSCs有非常良好的治疗效果,但是其治疗适应症、诊疗时机选择和作用机制等有待进一步研究。 最近,《Cell Death & Differentiation》杂志在线发表了中科

Baidu
map
Baidu
map
Baidu
map